Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Elevance Health Yönetim
Yönetim kriter kontrolleri 3/4
Elevance Health's CEO'su Gail Boudreaux, Nov2017 tarihinde atandı, in görev süresi 6.92 yıldır. in toplam yıllık tazminatı $ 21.89M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.3% maaş ve 92.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.047% ine doğrudan sahiptir ve bu hisseler $ 57.20M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.7 yıl ve 11.2 yıldır.
Anahtar bilgiler
Gail Boudreaux
İcra Kurulu Başkanı
US$21.9m
Toplam tazminat
| CEO maaş yüzdesi | 7.3% |
| CEO görev süresi | 6.9yrs |
| CEO sahipliği | 0.05% |
| Yönetim ortalama görev süresi | 6.7yrs |
| Yönetim Kurulu ortalama görev süresi | 11.2yrs |
Son yönetim güncellemeleri
Recent updates
Investors Continue Waiting On Sidelines For Elevance Health, Inc. (NYSE:ELV)
Sep 11
Elevance Health: Strong Earnings Growth Supports Strong Dividend Growth
Sep 06There's Been No Shortage Of Growth Recently For Elevance Health's (NYSE:ELV) Returns On Capital
Aug 29Here's Why We Think Elevance Health (NYSE:ELV) Is Well Worth Watching
Aug 02Elevance Health: Healthcare Services Segment Is Gaining Traction
Jul 31Elevance Health: Buy A Dividend Growth Machine
Jul 18Elevance Health: Favorable Trends Are Emerging (Rating Upgrade)
Jun 28Is Now An Opportune Moment To Examine Elevance Health, Inc. (NYSE:ELV)?
Jun 11Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher
May 27We Think Shareholders Will Probably Be Generous With Elevance Health, Inc.'s (NYSE:ELV) CEO Compensation
May 09Elevance Health (NYSE:ELV) Has Announced A Dividend Of $1.63
Apr 25Elevance Health: It's Not Too Late To Buy Their Dividend Growth
Apr 23Is Elevance Health (NYSE:ELV) Using Too Much Debt?
Apr 16Elevance Health: Not Doing Enough In 2024 To Justify Premium Price
Apr 11Elevance Health, Inc.'s (NYSE:ELV) Earnings Haven't Escaped The Attention Of Investors
Apr 01Elevance: A Healthy Dose Of Dividend Growth
Mar 21Elevance Heath: Financial Growth And Technical Strength Indicate A Buy
Mar 07Elevance Health (NYSE:ELV) Will Pay A Larger Dividend Than Last Year At $1.63
Feb 19Elevance Health: Time To Buy This Incredible Dividend Growth Stock
Jan 26Slowing Rates Of Return At Elevance Health (NYSE:ELV) Leave Little Room For Excitement
Jan 19Is Elevance Health (NYSE:ELV) A Risky Investment?
Jan 02Elevance Health, Inc.'s (NYSE:ELV) Shares Not Telling The Full Story
Dec 18A Look At Elevance's Margin Dynamics
Nov 23Is It Time To Consider Buying Elevance Health, Inc. (NYSE:ELV)?
Nov 16Elevance Health: A High Conviction Defensive Blue Chip Buy
Oct 19These 4 Measures Indicate That Elevance Health (NYSE:ELV) Is Using Debt Safely
Oct 04Elevance: Pave The Way For The Next UnitedHealth
Sep 21Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Sep 18Here's The Price I Would Buy Elevance Health Stock
Sep 13If EPS Growth Is Important To You, Elevance Health (NYSE:ELV) Presents An Opportunity
Aug 18Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
Aug 04Narrowing Down High-Quality Dividend Growth: Elevance Health Is Elemental
Jul 24Elevance Health: Beaten Down Share Price Offers Solid Potential
Jul 10Here's Why Elevance Health (NYSE:ELV) Can Manage Its Debt Responsibly
Jul 05Elevance Health: A Critical Update (Rating Downgrade)
Jun 05Elevance Health's (NYSE:ELV) Returns On Capital Are Heading Higher
Jun 04Is Now The Time To Look At Buying Elevance Health, Inc. (NYSE:ELV)?
May 05We Think Elevance Health (NYSE:ELV) Can Stay On Top Of Its Debt
Apr 04Elevance Health's (NYSE:ELV) Dividend Will Be Increased To $1.48
Feb 17Elevance Health (NYSE:ELV) Is Experiencing Growth In Returns On Capital
Feb 13Elevance Health: Attractive On Its Expansion Catalysts
Feb 09Elevance Health (NYSE:ELV) Has Announced That It Will Be Increasing Its Dividend To $1.48
Jan 28Elevance Health acquiring Blue Cross and Blue Shield of Louisiana
Jan 23Elevance Health Offers Great Value
Jan 17At US$483, Is Elevance Health Inc. (NYSE:ELV) Worth Looking At Closely?
Jan 17Elevance Health: Strong And Steady EPS Growth Ahead, High Relative Strength Name
Jan 02Elevance Health (NYSE:ELV) Seems To Use Debt Rather Sparingly
Nov 28CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | US$7b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$22m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$6b |
| Jun 30 2023 | n/a | n/a | US$6b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$21m | US$2m | US$6b |
| Sep 30 2022 | n/a | n/a | US$6b |
| Jun 30 2022 | n/a | n/a | US$6b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$19m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$4b |
| Mar 31 2021 | n/a | n/a | US$5b |
| Dec 31 2020 | US$17m | US$1m | US$5b |
| Sep 30 2020 | n/a | n/a | US$5b |
| Jun 30 2020 | n/a | n/a | US$6b |
| Mar 31 2020 | n/a | n/a | US$5b |
| Dec 31 2019 | US$15m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$4b |
| Jun 30 2019 | n/a | n/a | US$4b |
| Mar 31 2019 | n/a | n/a | US$4b |
| Dec 31 2018 | US$14m | US$1m | US$4b |
| Sep 30 2018 | n/a | n/a | US$5b |
| Jun 30 2018 | n/a | n/a | US$4b |
| Mar 31 2018 | n/a | n/a | US$4b |
| Dec 31 2017 | US$3m | US$162k | US$4b |
Tazminat ve Piyasa: Gail 'nin toplam tazminatı ($USD 21.89M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 13.04M ).
Tazminat ve Kazançlar: Gail 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Gail Boudreaux (63 yo)
6.9yrs
Görev süresi
US$21,889,039
Tazminat
Ms. Gail Koziara Boudreaux has been an Independent Director at Target Corporation since September 23, 2021. She has been President, Chief Executive Officer and Director of Elevance Health Inc. (formerly kn...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 6.9yrs | US$21.89m | 0.047% $ 54.1m | |
| Executive VP & CFO | less than a year | US$12.36m | Veri yok | |
| Executive VP and Chief Legal & Administrative Officer | 3.9yrs | US$8.11m | 0.0044% $ 5.1m | |
| Executive VP and President of Carelon & CarelonRx | 10.3yrs | US$6.98m | 0.0063% $ 7.2m | |
| Executive VP & President of Government Health Benefits | 6.3yrs | US$6.48m | 0.0098% $ 11.1m | |
| SVP, Treasurer & Chief Investment Officer | 6.5yrs | Veri yok | Veri yok | |
| Senior VP | 8.9yrs | Veri yok | 0.00057% $ 650.4k | |
| Vice President of Investor Relations | no data | Veri yok | Veri yok | |
| Senior Vice President of Public Affairs | 10.9yrs | Veri yok | Veri yok | |
| Chief Strategy Officer & Interim Chief Marketing Officer | less than a year | Veri yok | Veri yok | |
| Executive VP and President of Commercial & Specialty Health Benefits | no data | Veri yok | 0.0050% $ 5.7m | |
| President of Dental Business | 7.9yrs | Veri yok | Veri yok |
6.7yrs
Ortalama Görev Süresi
58yo
Ortalama Yaş
Deneyimli Yönetim: ELV 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.7 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 6.9yrs | US$21.89m | 0.047% $ 54.1m | |
| Independent Director | 19.9yrs | US$386.76k | 0.0024% $ 2.7m | |
| Independent Chair of the Board | 11yrs | US$597.83k | Veri yok | |
| Independent Director | 11.3yrs | US$362.53k | Veri yok | |
| Independent Director | 6.7yrs | US$371.42k | Veri yok | |
| Independent Director | 10.4yrs | US$371.42k | Veri yok | |
| Independent Director | 5yrs | US$347.28k | 0.0013% $ 1.5m | |
| Independent Director | 13.3yrs | US$360.34k | 0.0031% $ 3.6m | |
| Member of Advisory Board | 11.2yrs | Veri yok | Veri yok | |
| Member of Advisory Board | 11.2yrs | Veri yok | Veri yok | |
| Member of Advisory Board | 11.2yrs | Veri yok | Veri yok | |
| Member of Advisory Board | 11.2yrs | Veri yok | Veri yok |
11.2yrs
Ortalama Görev Süresi
68yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ELV 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 11.2 yıldır).